Hong Kong
· Delayed Price · Currency is HKD TransThera Sciences (Nanjing) Company Description
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases.
The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors.
It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases.
TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021.
The company was incorporated in 2014 and is headquartered in Nanjing, China.
| Country | China |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Frank Yongqian Wu |
Contact Details
Address: Building 9, Accelerator Phase 2 Nanjing, 210032 China | |
| Phone | 86 25 5821 6200 |
| Website | transthera.com |
Stock Details
| Ticker Symbol | 2617 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100006T02 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frank Yongqian Wu Ph.D. | Founder, Chief Executive Officer and Chairman |
| Di Wu | Vice President, Financial Controller and Executive Director |
| Songxi Cui | Vice President of Operations |
| Dr. Jing Fan | Chief Medical Officer |
| Jie Feng | Joint Company Secretary |
| Tik Wong CPA | Joint Company Secretary |